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Many investigators have observed that renal cal-
cium stones may be associated with uric acid disor-
ders. Prien and Prien [1] noted that patients with
gout who had stone disease frequently passed stones
which contained or were composed of calcium oxa-
late. Gutman 112] also observed a high frequency of
calcium oxalate stones in patients who had gout and
he called attention to crystallographic studies of
Lonsdale [3, 4] which showed that a significant
enough structural correspondence existed between
crystals of uric acid, sodium hydrogen urate, and
calcium oxalate to allow one to grow upon the sur-
face of another or to act for one another as heteroge-
neous seed nuclei. Dent and Sutor [5], on the other
hand, found that patients with calcium oxalate stone
disease were hyperuricemic more often than normal
subjects were, even though none of the patients had
clinical gout. Smith et al [61 made a similar observa-
tion and suggested that calcium stone-formers with
uric acid disorders represented a significant meta-
bolic subgroup of calcium stone disease.
Our own observation that hyperuricosuria was
very frequent among patients with calcium oxalate
nephrolithiasis [7, 8] was consonant with what had
come before and provided evidence for an abnormal-
ity of urine chemistry that could link uric acid disor-
ders to the formation of calcium stones in the kidney
or upper urinary tract. Subsequent research has cen-
tered mainly on hyperuricosuric calcium oxalate
stone-formers, because they have a decisive urine
chemistry abnormality and offer immediate research
opportunities. Study of such patients has provided
four kinds of evidence linking their hyperuricosuria
to calcium stone formation and setting them apart
from other calcium stone-formers. The evidence in-
cludes an atypical natural history of stone disease, in
vitro evidence for heterogeneous nucleation of cal-
cium oxalate crystallization by seed crystals of so-
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dium hydrogen urate or uric acid, a reduction by
urate or uric acid of the inhibiting effect which urine
normally has upon the aggregation of calcium oxalate
crystals, and an apparently dramatic effect of allopu-
rinol to reduce new stone formations. Taken alto-
gether, the weight of evidence supports the existence
of a distinct syndrome of hyperuricosuric calcium
oxalate nephrolithiasis.
Frequency of hyperuricosuria in calcium stone-formers
Before describing later and more specific research,
it seems worthwhile to review the basic statistical
association which, in large measure, initiated subse-
quent investigation. A recent survey of 460 calcium
oxalate stone-formers illustrates the very large frac-
tion of patients who excreted above 800 mg (men) or
750 mg (women) of uric acid in at least one of two 24-
hr urine samples collected for the purpose of making
such measurements (Table 1). Of the 121 hyperurico-
suric patients, 40 men (39%) and 4 women (22%)
were hyperuricemic by usual definition. Normal men
and women, who had no history of stone disease,
excreted such large amounts of uric acid only infre-
quently (Table 2). If higher limits are used, stone-
formers depart more drastically from normal sub-
jects, who rarely contributed values above 900 mg/24
hr (men) or 800 mg124 hr (women).
There is a natural difficulty in defining upper limits
of normal for uric acid excretion, because there is no
obvious bimodality to the distribution of excretion
rates among patients with stone disease or normal
people, but only a tendency, quite marked, for higher
values to occur in patients (Table 2). Gutman [2],
facing the same problem, suggested the limits of 800
and 750 mg for men and women, respectively, which
we have used to define hyperuricosuria. A point, 2
SD'S above the mean values of uric acid excretion by
our normal subjects of each Sex, could replace these
arbitrary limits, because only five percent of the
normal points depart so widely from the mean. But
such limits might not offer a diagnostically useful
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Idiopathic hypercalciuria 95 20.7
Marginal hypercalciuriaa 53 11.5
Hyperuricosuria 67 14.6
Hypercalciuria and hyperuricosuriab 54 11.7
Hyperuricemia alone 26 5.7
Primary hyperparathyroidism 24 5.2
Renal tubular acidosisc 17 3.7
Inflammatory bowel diseased 21 4.6
Medullary sponge kidney 7 1.5
Sarcoidosis 3 0.7
No disorder found 93 20.2
Total 460
Urine calcium > 140 mg/g creatinine
1) Marginal hypercalciuria not included
Distal, hereditary formd Regional enteritis, ulcerative colitis, granulomatous ileocolitis
advance, because the extent of urine saturation with
uric acid, sodium hydrogen urate, or both, deter-
mined mainly by the urine concentrations of the
substances and not by the amount excreted daily, is
the property which can influence crystallization in
the urine. Given the indirect relationship that exists
between uric acid excretion rate and uric acid con-
centration, it may be just as useful in predicting
supersaturation to use the lower limits that Gutman
proposed. These lower limits proved reasonably ef-
fective in selecting patients for treatment. Pak [91
has recently shown that urine was metastable with
respect to sodium hydrogen urate, as judged by a
concentration product ratio above 1, when total uric
acid concentration exceeded 300 mg/liter. This could
become the basis for clinical diagnosis of an abnor-
mal urine uric acid level, especially as urine sodium
concentration was deliberately kept low. An uncon-
trolled diet is likely to provide more sodium, increas-
ing the extent of supersaturation.
Mechanisms of hyperuricosuria
Excessive dietary purine intake, a natural mecha-
nism to explain so widespread a tendency to high
uric acid excretion rates, is a major factor. Uric acid
overproduction from endogenous purine metabolism
also contributes in some patients. A tubule defect of
urate reabsorption is an unattractive hypothesis in
view of the absence of hypouricemia in our patients.
Role of diet. We have estimated purine and calorie
intake by using the diaries of 10 men who were
normouricemic, hyperuricosuric calcium oxalate
stone-formers and five age- and weight-matched nor-
mal subjects who were drawn from a comparable
social and economic class. For 18 days, each person
Table 2. Frequency of various uric acid excretion rates among
calcium oxalate stone-formers (P) and normal subjects (N)
Men' Women
Urinary urate N P N P
mg/24 hr (N = 128) (N = 1046) (N = 77) (N = 302)
<200 0 0 0 0
200—400 2 1 36 25
400—600 38 17 54 53
600—800 48 50 9 8
800—900 6 14 0 6
900—1000 4 11 — 5
>1000 2 7 — 3
Numbers are the percentages of 24-hr urine samples containing
the amounts of urate indicated. Total number of urine samples in
each group is shown in parentheses.













a Values are means 1 SEM.
b F test for equality of variances = 9.16, P <0.01, for patients
vs. normal men.
kept a detailed diary of all foods consumed. Using
standard listings of purine and calorie contents of
foods and beverages, a nutritionist computed daily
intakes of both [101. The final conclusion (Table 3)
was that patients invested a higher proportion of
their dietary intake in purine-rich foods [111. By
chance, the average caloric intakes of patients and
controls were virtually identical. The specific diet
abnormality in patients was preferential consump-
tion of meat, fish, and poultry at the expense of
breads, grains, and starches.
Role of overproduction. In addition to consuming
excessive purine, some of the 10 patients we studied
appeared to overproduce uric acid. The 95 percent
confidence band relating urinary uric acid excretion
to dietary purine intake in normal people is shown as
the crosshatched area in Figure 1. Three of the 10
patients we studied excreted more uric acid than
would normal subjects eating the same amount of
purine. During days 8, 9, and 10 of a purine-free diet,
these three patients continued to excrete more uric
acid than normal subjects usually do, and certainly
more than the five normal subjects we studied,
shown by open circles. Presumably, the surplus uric
acid they excreted on their own high purine diet or a
purine-free diet reflected overproduction of uric acid













Fig. 1. Relationship between purine intake and uric acid excretion
in hyperuricosuric patients compared to normal subjects. The
crosshatched area denotes the 95% confidence band limits for the
normal regression. Data from three of the 10 patients (closed
circles) exceeded the upper limit of the band, indicating an abnor-
mal rate of uric acid excretion for the corresponding punne intake.
After seven days of a purine-free diet, these three patients contin-
ued to excrete an abnormal amount of uric acid, compared to the
five normal subjects (open circles). All values are means 1 SEM
of three separate determinations. Purine intake is expressed as
purine nitrogen. (Reprinted with permission from N EngI J Med
[8]).
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Natural history of stone disease
Idiopathic hypercalciuria, of marginal or severe
degree, occurred alone in 32.2% of calcium stone-
formers and in association with hyperuricosuria in
11.7%. Another 20.2% of patients had no discernible
metabolic defect, and 14.6% had only hyperurico-
suria (Table 1). Because of their numbers, it is possi-
ble to draw reasonably clear conclusions about the
natural history of stones in patients within these
metabolic subgroups. All of the remaining diseases
which cause calcium stones, including primary hy-
perparathyroidism, renal tubular acidosis, hyperox-
aluric states, and other, rarer, entities, are repre-
sented by too few patients for reliable measurement
of stone formation rates.
Hyperuricosuric patients formed the majority of
HU HU+IH IH MIH Neither
Number of patients 51 43 81 45 64
Percent men 81 90.5 71.5 67.6 69.5
Mean age at stone 35.6 33 33.3 35.2 36.3
onset, yr
Stones/patient 4.17 4.6 4.8 4.24 3.59
Stones/100 patients/ 64.9 53.1 41 37.7 42.8
yr
Hospitalizations/l00 33.8 16.1 17.1 27.7 21.7
stones
Cystoscopies/100 20.5 19.8 9.8 11.7 16.5
stones
Surgical procedures/ 16.8 14.1 13.4 17.3 13.4
100 stones
Abbreviations used are: HU, hyperuricosuria; IH, idiopathic
hypercalciuria; MIH, marginal hypercalciuria.
their stones at a slightly later average age than other
types of patients (Fig. 2). This was not due simply to
a later age of stone onset (Table 4) but mainly to a
more prolonged course of disease [121. The severity
of stone disease also was greater for hyperuricosuric
patients (Table 4); stone formation rates were higher,
and rates of cystoscopy and surgical procedures
were also higher, partly because of the greater num-
ber of stones formed and partly because of a higher
rate of complications for each 100 stones formed
[12]. The later onset and greater severity of their
stone disease support the notion that hyperuricosuric
calcium oxalate stone-formers constitute a separate
metabolic subclass of renal stone disease [12]. They
also suggest that treatment may be a more urgent
matter in hyperuricosuric than in other calcium oxa-
late stone-formers because their disease is likely to
be more severe and more protracted.
Urate-oxalate epitaxy
Lonsdale [3, 4] has summarized the most critical
data concerning structural similarities between uric
acid and calcium oxalate crystals. Anhydrous uric
acid crystals, commonly found as a constituent of
human stones [4], have network dimensions for their
100 face which are very close to those of the 001 face
of calcium oxalate monohydrate or the single face,
101, of calcium oxalate dihydrate crystals (Table 5).
For epitaxy to occur, the dimensions must match
within a few percent either directly or as an integral
multiple of one another. The percentage misfits for
the corresponding dimensions of the 001 face of
whewellite and the 100 face of uric acid dihydrate,
for example, are 1.1 and 1.6%, if one divides the
14.57 A dimension of whewellite by 2 to obtain the
closest integral result, 7.285. Both forms of uric acid
and calcium oxalate are well enough matched to
12
ill-
Table 4. Characteristics of stone disease in patients with










Fig. 2. Occurrence of calcium stones at various ages. Each point
shows the fraction of all stones formed by the population of
patients in each metabolic subgroup in each five-year age interval.
Open circles denote hyperuricosuria; X, hyperuricosuna and hy-
percalciuria; open triangles, hypercalciuria; open diamonds, mar-
ginal hypercalciuria; asterisks, no metabolic defect. Average age
at stone onset is shown in Table 4 for each subgroup. Peak stone
occurrence in hyperuricosuric patients occurred in the interval of
40 to 45 yr. The other groups had peak ages of 25—30 yr (no defect)
and 30—35 yr (hypercalciuria and admixed hypercalciuria and hy-
peruricosuria). Marginally hypercalciuric patients had three peaks
of stone formation, at 30—35, 40—45, and 55—60 yr of age. (Re-
printed with permission from JAMA [12]
Table 5. Geometrical correspondences between naturally
occurring faces of uric acid and calcium oxalate crystals
Dimensions
Face A
Uric acid 100 6.21 X 7.40
Uric acid 2 H20 100 6.35 X 7.40
Calcium oxalate H20° 001 6.28 X 14.57
Calcium oxalate 2 H20b 101 12.30 x 14.32
Whewellite, calcium oxalate monohydrate







Fig. 3. Heterogeneous nucleation of calcium oxalate by sodium
hydrogen urate seed crystals. A saturated solution containing 5mM
calcium and 200 sM '4C-sodium oxalate (pH, 5.7), 5 m barbitol-
acetate buffer, and 150 m potassium chloride was shaken at
24°C. At intervals, aliquots were filtered through 5-jL-diameter
filters, and the radioactivity of the filtrate was determined. In the
absence of seed crystal (.), precipitation began after 40 mm.
Sodium acid urate crystals (o), 0.1 mM/liter, greatly accelerated
precipitation; 2.5 mM/liter (.) was more effective. Equivalent
amounts of calcium oxalate monohydrate seed crystals (A and )
were far more effective, especially during the first few minutes. All
points are means 1 SEM of three determinations (Reprinted with



















































allow epitaxy in any order among them. Sodium
hydrogen urate is not listed in the table. However,
the sodium-oxygen distances in the sodium ion coor-
dination of the 100 face of the mono-hydrate are
2.384 and 2.535 A [131. The dimensions of the cal-
cium oxalate crystals (Table 5) are very close integral
multiples.
Direct evidence for nucleation of calcium oxalate
from aqueous solutions by uric acid and its salt has
been presented by Pak [14] and ourselves [151. In
our experiment, a metastable calcium oxalate solu-
tion, buffered at a pH of 5.7 in 5 m acetate barbitol,
was labelled with '4C-oxalate. Incubated with shak-
ing, the solution lost none of its labelled oxalate to
the solid phase over a 30-mm period (Fig. 3), as
judged by determining the 14C-radioactivity level of
aliquots passed through a 5-I pore diameter Milli-
pore filter, which would retain crystal nuclei. Addi-
tion of even small amounts of preformed sodium
hydrogen urate crystals caused a rapid loss of
counts, reflecting the accretion of oxalate to the solid
phase. Crystal growth, not adsorption of radio-
labelled oxalate to a urate surface, was occurring, as
shown by the absence of a fall in radioactivity when
calcium was omitted and, in separate experiments,
by simultaneous equimolar loss of oxalate and cal-
cium from the filtrate.
Uric acid seed crystals were also able to initiate
calcium oxalate crystal growth, although a lag phase
was present (Fig. 4), and initial growth appeared to
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from stone-formers and normal subjects often ap-
pears to be undersaturated or metastable with re-
spect to urate or uric acid, and that in the few cases
where uric acid concentrations were above the for-
mation product, calcium oxalate activity products
were high enough that crystallization of calcium oxa-
late could have occurred without a need for hetero-
geneous nucleation. Furthermore, by his calcula-
tions, urine would remain below the urate formation
product even if 2,000 mg of urate were excreted at a
pH of 6.3 in one liter of urine.
Pak et al [91, on the other hand, have provided
evidence that urine from patients with hyperurico-
suria is usually metastably supersaturated with re-
spect to sodium hydrogen urate. The formation prod-
4 uct of sodium hydrogen urate, however, has not been4 determined in urine. The values in urine may be
different from that determined in simple solution by
Robertson et al [141. Until the upper limit of metasta-
bility is known, the plausibility of urate crystals be-
having in vivo as heterogeneous nuclei is unknown.
In any event, the urine is itself an uncertain locale
for stone development. Nascent nuclei in urine will
tend to wash away, as their dimensions, even when
unusually large, are certainly below one millimeter,
compared to urinary structures many millimeters in
diameter. If mere growth and aggregation of newly
formed nuclei cause stones to form in the urine, the
bladder should be a frequent site of stones, whereas
it is in the kidneys themselves, in the calyces and on
the renal papillae, that most calcium stones are
formed. In order to develop there, stones must grow
on anchored nuclei. Nuclei could lodge in the niches
of calyces or infundibula. Alternatively, the open
ends of collecting ducts may plug with crystals that
form a permanent surface of anchored seed nuclei.
Terminal collecting ducts are about 200 to 300 in
diameter, with a luminal diameter of 20 to 60 .
Individual calcium oxalate crystals commonly ex-
ceed 12 in diameter and may approach 200 p. in
urine from stone-forming patients [171 and could
form a large enough mass to plug a duct. Even
though crystals may not attain sufficient size to cause
occlusion from heterogeneous nucleation alone (FIN-
LAYSON, this issue), the critical size may be achieved
by crystal aggregation or the impedance of urine
flow. Uric acid crystals can occlude even the ureter
under extreme conditions, and certainly do occlude
renal collecting ducts in some hyperuricosuric pa-
tients [181. It may be that detailed study of renal
tissue from stone-formers will reveal intratubular or
calyceal masses of urate that have been hitherto
overlooked, or that future studies of filtered urine
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Fig. 4. Nucleation of calcium oxalate by seed crystals of uric acid.
The pH of the system described in Figure 3 was altered to 4.4.
When unseeded (S) no precipitation of oxalate occurred dunng
two hours. Uric acid crystals (o), 2.5 mM/liter, promoted precipita-
tion, but less than did the same amount of calcium oxalate mono-
hydrate crystals (s). All values are means I SEM of three
experiments (Reprinted with permission from Proc Soc Exp Biol
Med [15]).
be slower. With time, crystal growth rose toward the
level seen with sodium hydrogen urate. These
experiments were performed at a pH of 4.4, rather
than at a pH of 5.7, to prevent conversion of uric acid
to urate. Unseeded, the system remained stable for a
longer period than at the higher pH values used for
the urate experiments, and growth of added, pre-
formed, calcium oxalate crystals was also slower.
The difference in growth rates with both seed crys-
tals makes it difficult to compare the effects of urate
and uric acid directly.
The role of heterogeneous nucleation in vivo is
uncertain. Sodium hydrogen urate crystals are not
seen in fresh warm human urine, which raises a
natural barrier to the direct extension of the present
in vitro studies to human stone disease. Further-
more, Robertson et al [16] have shown that urine
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not rare. Alternatively, it may be that uric acid itself,
which surely does plug tubules and may produce
copious crystalluria, is an important source of heter-
ogeneous nuclei which compensate for their ineffi-
ciency by being widely distributed.
The potential importance of heterogeneous nuclei
from calcium oxalate is much greater in urine than it
would be in simple salt solution because urine con-
tains potent inhibitors of nucleation and crystal
growth which raise the formation product and slow
the growth of calcium oxalate nuclei, retarding the
development of an appreciable crystal mass [191.
One of these inhibitors is inorganic pyrophosphate
[201; the other(s), one or more larger molecules [211,
are of uncertain composition. These inhibitors do not
affect uric acid or sodium hydrogen urate, which
crystallize in urine at the same rate as in a similarly
constructed salt solution.
Reduced urine inhibitors
Robertson [17] has recently presented evidence
for the intriguing idea that sodium acid urate may
promote calcium oxalate stone disease by forming a
gel phase in urine which adsorbs or interferes with
naturally occurring urine inhibitors of calcium oxa-
late crystal growth, inhibitors which he believes may
be acid mucopolysaccarides (AMP's) [191. His
method for measuring inhibitors is to observe the
effects of one percent urine on the rate at which seed
crystals of calcium oxalate grow and aggregate in a
metastable calcium oxalate solution. He has ob-
served that urines which contain more urate have
less inhibitory effect per milligram of AMP's than
urines with lower urate concentrations, a rather indi-
rect fact whose interpretation depends upon the un-
proven assumption that AMP is the major inhibitor
present and not merely one of many inhibitors. A
more direct demonstration which he has presented is
that urate added to urine in vitro reduces, and re-
moval of urate restores inhibitory activity [17, 191,
but as yet this has not been documented in detail,
only described in an overall review fashion. More-
over, this interpretation should be made with cau-
tion, since studies were performed in diluted urine
and not whole urine. (see Dr. Finlayson's article and
Dr. Fleisch's article, this issue).
These observations may be of extreme impor-
tance. If generally correct, they could explain the
syndrome of hyperuricosuric calcium oxalate stones
without a need to invoke massive urate or uric acid
crystalluria, neither of which are especially common
in the urine of calcium oxalate stone-formers. In-
stead, one could envision the urate (or uric acid) as a
stable gel suspension which may be undetected dur-
ing routine urine microscopy. The problem of an-
chored nuclei is also lessened as, uninhibited by the
usual properties of urine, calcium oxalate crystal
nuclei could more readily grow and aggregate to
occlude collecting ducts in the renal papillae or lodge
in calyces. Reduced inhibition could also explain the
critical, and as yet unpublished, observations by Pak
that induction of hyperuricosuria leads to producing
a urine in which the formation product for calcium
oxalate, usually very elevated in urine compared to
simple salt solutions, presumably because of the in-
hibitors urine contains, is reduced towards levels
seen in simple media. Heterogeneous nucleation
could cause such a reduction of formation product,
but so could a reduction of inhibitory activity. Unfor-
tunately, AMP's probably do not cause inhibition of
nucleation of calcium oxalate (FLEISCH, this issue), a
fact that reduces the attractiveness of the hypothesis.
An alternative hypothesis, which incorporates cer-
tain features from both theories, is that the colloidal
urate itself may participate in heterogeneous nuclea-
tion of calcium oxalate [91.
Allopurinol treatment
Perhaps the most dramatic evidence linking hyper-
uricosuria to calcium oxalate stones is the seeming
ability of allopurinol to reduce new stone formation
far below pretreatment rates. Thus far, we have
observed 48 patients with recurrent calcium stones
who had hyperuricosuria as the sole detected meta-
bolic disorder and who were treated with allopurinol
for at least one year [221. Before treatment, these
patients formed 67.1 stones/100 patient years (Table
6) and therefore would be expected to form 124.8
Table 6. Effects of allopunnol treatment in patients with
hyperuricosunc calcium oxalate stonesa,!)
Untreated
HU IH+HU patients
Number of patients 48 42 34
Pretreatment interval, patient 298 357 292
years
Pretreatment stones 200 188 123
Stones/patient 4.17 4.48 3.62
Years/patient 6.21 8.5 8.6
Stones/100 patients/yr 67.1 52.7 42.2
Treatment interval, patient 186 119 109
years
Years/patient 3.88 2.83 3.21
New stones formed 8 6 29
Predicted new stones 124.8 62.7 46.2
New stones/predicted, % 6.4 9.6 62.8
x2 predicted vs. observed 109.3 51.3 6.4
P <0.001 <0.001 <0.05
a These patients are the subset of those shown in Tables I and 4
for whom detailed follow-up data were available.
b Abbreviations used are: HU, hyperuricosuria; IH, idiopathic
hypercalciuria.
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stones during the 186 patient years of treatment if the
pretreatment stone production rate continued to ap-
ply. Tn fact, they formed only eight stones (Fig. 5) (xt
= 109.3, P 0.001), indicating that stone production
rate had altered greatly.
The interpretation of these results is limited by the
absence of a parallel control population, with the
same characteristics, left untreated; factors other
than allopurinol may have produced the fall in stone
production. Some estimate of the likely effects of
nonspecific factors such as diet, better attention to
fluid intake, avoidance of dehydration, and contin-
ued contact with the stone clinic can be derived from
the response of a separate group of calcium stone-
formers, who had no detectable metabolic disorders
and, therefore, were given no specific form of
treatment.
This group of 34 patients had a less active form of
stone disease before entering the program (Table 6),
a fact mentioned previously. During the follow-up
interval, new stone formation declined, so that only
62.8% of the stones that would have been predicted
actually occurred (Fig. 6). This suggests that nonspe-
cific factors related to our follow-up program proba-
bly do foster a moderate decline in stone formation,
but one that is far less impressive than that which
occurs with allopurinol. Even though these 34 pa-
tients were relatively less active before entering the
program, compared to hyperuricosuric patients, they
formed nearly 10 times more stones per 100 patients
per year during the follow-up interval, suggesting
that allopurinol treatment did indeed appear to con-
tribute to stone prevention in hyperuricosuric patients.
Because it is a common disorder, hyperuricosuria
was often found to coexist with idiopathic hypercal-
ciuria in a single patient [22]. Their coexistence was
almost precisely what would be expected by chance
alone, given their independent rates of occurrence.
In this group of patients, the only treatment data
available were based upon combined use of thiazide,
an agent that has an established effect to lower urine
calcium excretion [23], and allopurinol. These com-
bined treatment data, which show a marked fall in
stone production (Table 6, Fig. 7), are mainly confir-
matory; either agent alone may well have been suffi-
cient, and only a failure of treatment, which would
be unexpected, could have any major impact upon
the hypothesis that hyperuricosuria may contribute
to calcium stone production.
Smith [24] has performed a controlled, random-
ized prospective study based upon allopurinol treat-
ment of calcium oxalate stone-formers who had
serum urate concentrations above 6 mgIlOO ml, with
Fig. 6. The course of calcium oxalate stone disease in untreated
patients. Symbols are the same as in Figure 5; statistics are shown
in Table 6. Despite contact with the stone clinic and advice
concerning diet and dehydration, new stone production was re-
duced by only 37.2% compared to the nearly ten-fold reduction
observed in the allopurinol-treated patients. (Reprinted with per-
mission from Ann Intern Med [221.)
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Fig. 5. The effect of allopurinol upon new stone production in
hyperuricosuric patients. Each of 48 patients is shown as a hori-
zontal line. Single (X) and multiple (0) events are shown. New
stone production was greatly reduced during treatment. The statis-
tical details are shown in Table 6. Allopurinol was given 100 mg
twice daily except in three subjects who required 300 mg/day to
reduce hyperuricosuria. (Reprinted with permission from Ann
Intern Med [22].)
Fig. 7. Effects of combined allopurinol and thiazide treatment of
patients with hyperuricosuria and hypercalciuria. Symbols are the
same as in Figures 5 and 6; statistics are in Table 6. Combined
treatment lowered stone recurrence dramatically. The thiazide
used was trichlormethiazide, 2 mg twice daily; allopurinol was
given 100 mg twice daily. (Reprinted with permission from Ann
Intern Med [221.)
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Table 7. Effects of allopurinol on new stone production by
recurrent calcium oxalate stone-formers with serum urate
concentrations above 6 mg/100 mia
Placebo-
Allopurinol- treated
Year of treated patients patients
follow-up stone-free alP' stone-free all x2e JJ
Start of study 49 49 43 43 — —
0.5 28 49 13 43 6.57 <0.01
1 27 38 3 27 20.70 <0.001
2 20 30 1 20 16.84 <0.001
3 17 23 1 13 14.54 <0.001
4 15 19 1 12 14.73 <0.001
5 10 12 1 5 5.97 <0.02
a This data is adapted from a study by Pak (personal communi-
cation). Numbers reflect patients who have or have not formed
new stones at each follow-up interval.
This includes all patients remaining in this study; some were
lost due to failure of treatment compliance, personal decisions to
leave the study, or drug intolerance. Patients entered the study at
different times and therefore had varying lengths of total follow-
up.
Calculated x2 was for placebo- vs. allopurinol-treated patients;
P values are for one degree of freedom.
or without hypeniricosuria. Apparently, hypercal-
ciuric patients were excluded. The principle data
from the study are summarized in Table 7. The
number of stone-free, placebo-treated patients fell
rapidly, from 13 patients at six months to one patient
at one year; among the allopurinol-treated patients,
the fraction of stone-free patients remained signifi-
cantly more elevated throughout the study. The dif-
ference in occurrence of stone-free patients for each
of the five years, tested by the x2 method, was
significant at each interval. Smith divided the pa-
tients who continued to form new stones into those
who improved, by which was meant a reduced rate
of new stone production, and those who were un-
changed. These two categories, which were distin-
guished on subjective grounds, and on the basis of
the number of stone events in single subjects, a small
and highly variable index which is notoriously capri-
cious for stone disease, are not analyzed separately
in the table.
Though quantitatively different from our own,
these results lead to the same basic conclusion. In
each year, 20 to 35% of treated patients formed new
stones, whereas overall recurrence was below 10%
in our 48 treated patients with hyperuricosuric cal-
cium oxalate stones; still, Smith's data demonstrate
an impressive allopurinol treatment effect. Quantita-
tive differences in the magnitude of the effect could
easily have arisen from the different patient popula-
tions studied. Our patients all were hyperuricosuric;
some were hyperuricemic and some were not. In
Smith's study [24], the selection criterion (serum
urate level above 6 mgI 100 ml) could have included
many patients whom we would have classified as
idiopathic stone-formers.
The problem of selection is far from trivial, be-
cause both proposed mechanisms of stone produc-
tion, heterogeneous nucleation and reduction of in-
hibitor activity, depend upon abnormally elevated
urinary urate or uric acid concentrations, and though
patients with normal urine urate levels could benefit
from allopurinol by virtue of a reduction in the back-
ground effects which even normal amounts of urate
may produce, the magnitude of the therapeutic re-
sponse would predictably be reduced to the extent
that factors other than the effects of urate were
responsible for stones. Given this mechanism for
potential degradation of allopurinol effect, the signifi-
cant decrease in new stone production from allopuri-
nol which Smith observed supports the notion that
this drug, probably because of its effects upon uri-
nary urate level, is an efficient treatment for certain
forms of calcium oxalate stone disease.
Conclusion
It seems evident that a variety of observations
support the existence of a new, gradually evolving,
syndrome which may be called hyperuricosuric cal-
cium oxalate nephrolithiasis. It consists of calcium
oxalate stones, hyperuricosuria, and the absence of
any of the well defined causes of calcium oxalate
stones, such as hypercalciuric states, primary hyper-
parathyroidism, hyperoxaluria from any cause, and
medullary sponge kidney disease. It seems to affect
mainly men and is caused by a combination of di-
etary purine excess and, in some cases, endogenous
uric acid overproduction. Stone disease is maximal
during the fourth and fifth decades of life and is often
of unusual severity. Allopurinol therapy appears to
be an effective form of treatment, although this has
not yet been established by a controlled, prospective
study but only by prospective observation of treated
patients. The mechanism linking hyperuricosuria to
calcium oxalate stone production is not known; but
heterogeneous nucleation of calcium oxalate by crys-
tals of sodium hydrogen urate or uric acid, in the
urine, in the calyceal niches, or at the open ends of
plugged renal collecting ducts, is one attractive hy-
pothesis that is supported by some in vitro evidence.
Attenuation of urinary crystal growth inhibitors by
an excess of urinary urate, perhaps existing in the
form of a gel, is another.
The true prevalence, clinical importance, and co-
hesiveness of the syndrome are all uncertain. Our
data suggest a prevalence of about 20 to 30%, either
alone or associated with idiopathic hypercalciuria.
Prevalence will generally reflect diet, so the affluent
may well suffer more frequently from hyperurico-
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suria and its presumed consequences than will the
poor. The syndrome may also vary in importance
with time, depending upon cultural patterns of diet in
this country and elsewhere. The clinical importance
of the syndrome is supported mainly by the apparent
success of allopurinol treatment. If this can be repro-
duced during a fully controlled study, confidence in
the value of long term treatment will be much in-
creased. Dietary measures have never been evalu-
ated as a treatment measure. They may be as effec-
tive as allopurinol, and they offer the obvious
advantage of simplicity and avoidance of a drug.
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